Back to results
US 2003/0228628 A1Published application
Diagnosis and treatment of human dormancy syndrome
OwnerMichael Powellinventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerMichael Powellinventor
Estimating the term…
New methods for diagnosis of human dormancy syndrome are provided. Human dormancy syndrome is characterized by elevated serum ratio of rT3/fT3 compared to a population of normal subjects from which subjects suffering from fibromyalgia, chronic fatigue, obesity, dementias including Alzheimer's Disease and related dormancy conditions are excluded, and the presence of one or more findings related to reduced activity including torpor, chronic fatigue, insulin resistance, dementias, obesity and the like. Treatment of human dormancy syndrome is directed toward increasing fT3 levels or decreasing rT3 levels, or both, using pharmaceutical and/or behavioral methods. Other conditions that are associated with HDS can also be treated using T3 therapy, with or without specific psychological, behavioral or pharmaceutical therapies.
A method for diagnosing human dormancy syndrome in a human, comprising the steps of:
A method for treating human dormancy syndrome in a patient, comprising:
A method for treating human dormancy syndrome in a patient, comprising:
A method for treating human dormancy syndrome in a patient, comprising stimulating the enzyme 5′-D1 to increase T3 production so that the ratio of serum rT3/fT3 decreases to below about 6.
A method for treating human dormancy syndrome in a patient, comprising inhibiting the enzyme 5-D1 and stimulating at least one of the enzymes 5′-D2 and 5′-D1 so that the ratio of serum rT3/fT3 is below about 6.
A method for treating human dormancy syndrome in a patient, comprising administering T3 to decrease the ratio of serum rT3/fT3 to below about 6.
A method for treating dementia, comprising the steps of:
Dependencies are inferred from the claim text.